title: Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
abstract: BACKGROUND
  Alpha-fetoprotein (AFP) has been used as a diagnostic biomarker for hepatocellular carcinoma (HCC), but its prognostic significance is not well defined. This study was performed to classify the prognostic significance of AFP status in HCC patients after transarterial chemoembolization (TACE).
  
  
  METHODS
  Four hundred forty-one HCC patients from a prospective maintained database with pathologic confirmation including 139 with normal AFP levels and 302 with elevated AFP levels were retrospectively studied for prognostic significance of AFP in treatment response and survival after TACE. Univariate and multivariate analyses were used to identify the prognostic factors.
  
  
  RESULTS
  There were significant differences in overall survival (OS) after TACE between AFP-negative and AFP-positive HCC patients when the AFP cutoff value was defined as 20 ng/ml (P < 0.0001). Among the AFP-positive patients, different AFP levels had no significantly prognostic effects on OS after TACE (P = 0.093). Multivariate analysis revealed that AFP status for AFP-negative or positive was an independent prognostic factor for HCC patients after TACE (P = 0.001), along with γ-glutamyltransferase (GGT) level (P = 0.004) and tumor diameter (P < 0.0001). In addition, there were significant differences in clinicopathologic features between AFP-positive and AFP-negative patients with regard to age, gender, alanine transferase level, GGT level, tumor diameter, and Barcelona Clinic Liver Cancer stage.
  
  
  CONCLUSIONS
  Compared with AFP-positive HCC patients, patients with AFP-negative status have a better treatment response and prognosis after TACE.
authors.affiliation: Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, People's Republic of China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Yi
authors.initials: Y
authors.lastname: Chen
authors.forename: Ningling
authors.initials: N
authors.lastname: Ge
authors.forename: Lan
authors.initials: L
authors.lastname: Zhang
authors.forename: Xiaoying
authors.initials: X
authors.lastname: Xie
authors.forename: Jubo
authors.initials: J
authors.lastname: Zhang
authors.forename: Rongxin
authors.initials: R
authors.lastname: Chen
authors.forename: Yanhong
authors.initials: Y
authors.lastname: Wang
authors.forename: Boheng
authors.initials: B
authors.lastname: Zhang
authors.forename: Jinglin
authors.initials: J
authors.lastname: Xia
authors.forename: Yuhong
authors.initials: Y
authors.lastname: Gan
authors.forename: Zhenggang
authors.initials: Z
authors.lastname: Ren
authors.forename: Shenglong
authors.initials: S
authors.lastname: Ye
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D002945:Cisplatin / Q000008:administration & dosage; D004998:Ethiodized Oil / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000097:blood* / Q000473:pathology / Q000628:therapy*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D015999:Multivariate Analysis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D047368:Tumor Burden; D000509:alpha-Fetoproteins / Q000378:metabolism*; D005723:gamma-Glutamyltransferase / Q000097:blood
chemical_list: D000970:Antineoplastic Agents; D000509:alpha-Fetoproteins; D016685:Mitomycin; D004998:Ethiodized Oil; D005723:gamma-Glutamyltransferase; D002945:Cisplatin; D005472:Fluorouracil